| Identification | Back Directory | [Name]
Cefpiramide acid | [CAS]
70797-11-4 | [Synonyms]
CEFPIRAMIDE
cefpiramide acid
Suncefal：Sepatren
Cefpiramide (300 mg)
7-aMino-3-(1-Methyl-1-pyrroleane oniuM acids)Methyl-2-oxacepheMs-2-Carboxylic Acid Hydrochloride
7-[2-[(4-hydroxy-6-methylpyridine-3-carbonyl)-amino]-2-(4-hydroxy phenyl)-acetylamin]-3-(1-methyl-1H-tetrazole-5-thiomethyl)-8-keto-5-thiox-1-azole[4.2.0]octadiene-2-carboxylic acid
7-[2-[(4-hydroxy-6-methylpyridine-3-carbonyl)-amino]-2-(4-hydroxy phenyl)-acetylamin]-3-(1-methyl-1h-tetrazole-5-thiomethyl)-8-keto-5-thiox-1-azole[4.2.0]octadiene-2-carboxylic acid
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-[[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6α,7β(R*)]]-
(6R,7R)-7-[(2R)-2-(4-hydroxyphenyl)-2-[(6-Methyl-4-oxo-1,4-dihydropyridin-3-yl)forMaMido]acetaMido]-3-{[(1-Methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]Methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C25H24N8O7S2 | [MDL Number]
MFCD00864893 | [MOL File]
70797-11-4.mol | [Molecular Weight]
612.64 |
| Chemical Properties | Back Directory | [Melting point ]
213-215° (dec) | [density ]
1.75±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer, Under Inert Atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
2.62±0.50(Predicted) | [color ]
White | [InChIKey]
PWAUCHMQEXVFJR-PMAPCBKXSA-N | [SMILES]
N12[C@@]([H])([C@H](NC([C@H](NC(C3=C(O)C=C(C)N=C3)=O)C3=CC=C(O)C=C3)=O)C1=O)SCC(CSC1N(C)N=NN=1)=C2C(O)=O |
| Hazard Information | Back Directory | [Chemical Properties]
Yellow crystals, melting point 213-215°C (decomposition).
Cefpiramide Sodium (Cefpiramide Sodium): C25H23N8O7S2Na. [74849-93-7]. White to yellowish-white crystalline powder, odorless, bitter. Very soluble in dimethylformamide, freely soluble in water, slightly soluble in methanol, very slightly soluble in ethanol, practically insoluble in chloroform, acetone, tetrahydrofuran, acetonitrile, or n-hexane. | [Uses]
Antibacterial. | [Definition]
ChEBI: A third-generation cephalosporin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and (R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectiv
ly, of the cephem skeleton. It has a broad spectrum of antibacterial activity. | [Antimicrobial activity]
A semisynthetic parenteral cephalosporin. It exhibits a broad
range of activity, which includes Ps. aeruginosa, though the overall activity is rather modest. It is moderately
stable to most β-lactamases but less so than ceftazidime or
cefpirome.
In volunteers given 0.5 or 1 g by intravenous bolus, the mean
plasma concentration shortly after injection was around 150 or
300 mg/L, respectively. There was no accumulation when the
same doses were repeated every 12 h for 11 doses. It is highly
bound to plasma protein (c. 95%). The mean plasma half-life
is around 5 h. Less than one-quarter of the dose appears in the
urine over 24 h; the rest is excreted in bile and high concentrations
are found in feces. Renal impairment has little effect on
elimination in patients with normal liver function.
Diarrhea may be associated with marked suppression of
gut flora resulting from biliary excretion of the drug. The molecule
includes a C-3 methylthiotetrazole side chain and side
effects associated with that substituent are to be expected.
It is available in Japan. | [Synthesis]
(1) Sodium compound D-a-(4-hydroxy-6-methylnicotinamide)-P-hydroxyphenylacetate was dissolved in an organic solvent and activated by an activator catalyzed by a base at a temperature of -25 to -20°C to produce a solution of mixed anhydride (a);
(2) | [in vivo]
Cefpiramide (25 mg/kg; i.v.; once) shows anti-Streptococcus pneumoniae activity in experimental pneumococcal meningitis[2].
Cefpiramide (25 mg/kg; i.v.; once) reduces bacteria in CSF more than 10[4] CFU/ml[2]. | Animal Model: | New Zealand white male rabbits(2-3 kg)[2]. | | Dosage: | 25 mg/kg | | Administration: | Intravenous injection; once. | | Result: | Anti-Streptococcus pneumoniae. |
| [IC 50]
β-lactam |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
|